Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898037 | 1.00 | GPR119 (0.54) | GPR119KCNH2HRH3GPR183DPP4 | |
| SCHEMBL2899728 | 0.93 | GPR119 (0.48) | GPR119KCNH2HRH3GPR183DPP4 | |
| SCHEMBL2899724 | 0.93 | GPR119 (0.48) | GPR119KCNH2HRH3GPR183DPP4 | |
| SCHEMBL2898615 | 0.89 | GPR119 (0.48) | GPR119KCNH2GPR183DPP4DPP8 | |
| SCHEMBL2898618 | 0.89 | GPR119 (0.48) | GPR119KCNH2GPR183DPP4DPP8 | |
| SCHEMBL2899804 | 0.89 | GPR119 (0.53) | GPR119KCNH2HRH3GPR183 | |
| SCHEMBL2899807 | 0.89 | GPR119 (0.53) | GPR119KCNH2HRH3GPR183 | |
| SCHEMBL8071676 | 0.88 | GPR119 (0.55) | GPR119KCNH2HRH3GPR183 | |
| SCHEMBL2891740 | 0.87 | GPR119 (0.49) | GPR119KCNH2HRH3 | |
| SCHEMBL2891746 | 0.87 | GPR119 (0.49) | GPR119KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | GPR119 1/4885KCNH2 2784/4885HRH3 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.